Zacks Investment Research
28 Oct 2026, 16:46 UTC · 1h ago
GSK Q3 Earnings Top Mark, Stock Down on Soft Vaccines Sales
Impact · against what's priced in
GSK's Q3 results are mixed; strong growth in HIV and oncology is offset by a concerning decline in the Vaccines segment. While the earnings beat is positive, the softness in a core portfolio pillar creates a drag on the overall outlook.
- GSK+0.10
No priced-in read yet
- In context
Strong 15% growth in Specialty Medicines, specifically in HIV and Oncology, is partially offset by a 2% decline in the critical Vaccines segment.
Read from the article alone
